Advertisement

Emerging Therapies in Metastatic Prostate Cancer

  • Daniel W. Sonnenburg
  • Alicia K. Morgans
Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Genitourinary Cancers

Abstract

Purpose of Review

In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy.

Recent Findings

Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy. A single-arm phase 2 study of the PARP inhibitor olaparib demonstrated high response rates and more favorable progression-free and overall survival for men with metastatic castration-resistant prostate cancer and DNA repair defects treated with olaparib compared with men without DNA repair defects. Multiple ongoing clinical trials are investigating novel hormonal therapies and combinations of chemotherapy, targeted small molecules, immunotherapy, and radiopharmaceuticals.

Summary

Progress continues to be made in the treatment of metastatic prostate cancer, and ongoing clinical trials continue to investigate novel agents and approaches to treatment.

Keywords

Metastatic hormone-sensitive prostate Cancer Metastatic castration-resistant prostate Cancer Chemohormonal therapy Hormonal therapy Targeted small molecules Immunotherapy Radiopharmaceuticals Targeting DNA repair defects 

Notes

Compliance with Ethical Standards

Conflict of Interest

Daniel Sonnenburg declares that he has no conflict of interest.

Alicia Morgans has received compensation from Genentech, Bayer, and AztraZeneca for participation on advisory boards, and has received compensation from Janssen for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). . Prostate Cancer SEER Cancer Statistics Review, 1975-2014. 2017.Google Scholar
  2. 2.
    • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373(8):737–46.  https://doi.org/10.1056/NEJMoa1503747. This trial showed that the addition of six cycles of docetaxel to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial Ann Oncol 2016;27(Supplemental 6).Google Scholar
  4. 4.
    • James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.  https://doi.org/10.1016/S0140-6736(15)01037-5. This trial showed that the addition of six cycles of docetaxel to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.  https://doi.org/10.1056/NEJMoa1702900.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.  https://doi.org/10.1056/NEJMoa1704174. This trial showed that the addition of abiraterone and prednisone to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival. CrossRefPubMedGoogle Scholar
  7. 7.
    Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(3):338–48.  https://doi.org/10.1016/S1470-2045(15)70027-6.CrossRefPubMedGoogle Scholar
  8. 8.
    Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015;33(7):723–31.  https://doi.org/10.1200/JCO.2014.56.5119.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014;15(6):592–600.  https://doi.org/10.1016/S1470-2045(14)70129-9.CrossRefPubMedGoogle Scholar
  10. 10.
    Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Long-term anti-tumor activity and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 3-year, open-label, follow-up results. J Urol. 2017;199:459–64.  https://doi.org/10.1016/j.juro.2017.08.103. CrossRefPubMedGoogle Scholar
  11. 11.
    McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, et al. A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. J Clin Oncol. 2016;34(16):1913–20.  https://doi.org/10.1200/JCO.2015.65.3154.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534–40.  https://doi.org/10.1200/JCO.2011.39.4767.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Draeger B, et al. CDK4/6 inhibitors in cancer therapy: a novel treatement strategy for bladder Cancer. Bladder Cancer. 2017;3(2):79–88.  https://doi.org/10.3233/BLC-170105.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Chi K AM, Sunderland K, et al. A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2017;35:abstract 5002.Google Scholar
  15. 15.
    Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975–85.  https://doi.org/10.1016/S1470-2045(14)70240-2.CrossRefPubMedGoogle Scholar
  16. 16.
    Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther. 2015;14(1):59–69.  https://doi.org/10.1158/1535-7163.MCT-14-0521.CrossRefPubMedGoogle Scholar
  17. 17.
    Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7(269):269ra2.  https://doi.org/10.1126/scitranslmed.3010563.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–53.  https://doi.org/10.1056/NEJMoa1603144.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28.  https://doi.org/10.1016/j.cell.2015.05.001.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708.  https://doi.org/10.1056/NEJMoa1506859.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hussain M, Daignault S, Twardowski P, et al. Abiraterone + prednisone +/- veliparib for patients with metastatic castration-resistant prostate cancer: NCI 9012 updated clinical genomics data. American Society of Clinical Oncology annual meeting (abstract 5001). 2017.Google Scholar
  22. 22.
    Bono JSD, Hussain M, Thiery-Vuillemin A, Mateo J, Sartor AO, Chi KN et al. PROfound: a randomized phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration. Journal of Clinical Oncology. 2017;35(15_suppl):TPS5091-TPS. doi: https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS5091.
  23. 23.
    Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112(3):521–6.  https://doi.org/10.1002/cncr.23195.CrossRefPubMedGoogle Scholar
  24. 24.
    Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621–30.  https://doi.org/10.1158/1078-0432.CCR-12-3791.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–84.  https://doi.org/10.1038/nrc2167.CrossRefPubMedGoogle Scholar
  26. 26.
    Kennedy RD, D’Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24(23):3799–808.  https://doi.org/10.1200/JCO.2005.05.4171.CrossRefPubMedGoogle Scholar
  27. 27.
    Corn PG, et al. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2015;33(suppl; abstr 5010):2015.Google Scholar
  28. 28.
    Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–13.  https://doi.org/10.1200/JCO.2015.65.5597.CrossRefPubMedGoogle Scholar
  29. 29.
    De Bono J, De Giorgi U, Massard C, et al. Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study). Journal of Clinical Oncology. 2016;34 supplemental(Abstract 5017).Google Scholar
  30. 30.
    Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7(33):52810–7.  https://doi.org/10.18632/oncotarget.10547. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12.  https://doi.org/10.1016/S1470-2045(14)70189-5.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–7.  https://doi.org/10.1200/JCO.2016.69.1584.CrossRefPubMedGoogle Scholar
  33. 33.
    Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105.  https://doi.org/10.1200/JCO.2009.25.0597.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Jha GG, Gupta S, Tagawa ST, Koopmeiners JS, Vivek S, Dudek AZ, et al. A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2017;35(15_suppl):3066.  https://doi.org/10.1200/JCO.2017.35.15_suppl.3066.Google Scholar
  35. 35.
    Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.  https://doi.org/10.1056/NEJMoa1213755.CrossRefPubMedGoogle Scholar
  36. 36.
    Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91.  https://doi.org/10.1158/1078-0432.CCR-13-0231.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Daniel W. Sonnenburg
    • 1
  • Alicia K. Morgans
    • 1
  1. 1.Northwestern University Feinberg School of MedicineDivision of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer CenterChicagoUSA

Personalised recommendations